Given the recent approval of 2 PSMA imaging agents and the high incidence and prevalence of prostate cancer, the most common malignancy in men, it is very likely that many men will undergo PSMA PET imaging after a recent COVID-19 vaccination. This evidence concerns the gene FOLH1 and prostate cancer.